

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/681,855
				Filing Date	October 7, 2003
				First Named Inventor	Mark D. BEDNARSKI
				Group Art Unit	1614
				Examiner Name	not yet assigned
Sheet	1	of	3	Attorney Docket Number	RADO-001/02US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number (if known)			
/JDA/	P1	5,970,974		Van Der Linden, Klaus	10-26-1999
/JDA/	P2	5,954,047		Armer, Thomas Alex	09-21-1999
/JDA/	P3	5,950,619		van der Linden, Klaus	09-14-1999
/JDA/	P4	5,698,155		Grosswald, Ralph R.	12-16-1997
/JDA/	P5	5,579,458		Yokosuka, Hirobumi	11-26-1996
/JDA/	P6	5,556,611		Biesalski, Hans K	09-17-1996
/JDA/	P7	5,112,598		Biesalski, Hans K.	05-12-1992
/JDA/	P8	4,765,539		Noakes, Timothy J.	08-23-1988
/JDA/	P9	3,916,899		Theeuwes, Felix	11-04-1975
/JDA/	P10	3,845,770		Theeuwes, Felix	11-05-1974

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code ³	Number ⁴	Kind (if known)			

Examiner Signature	/James Anderson/	Date Considered	09/12/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (08-00)

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/681,855
				Filing Date	10/07/2003
				First Named Inventor	Mark D. BEDNARSKI
				Group Art Unit	1614
				Examiner Name	Not yet assigned.
Sheet	2	Of	3	Attorney Docket Number	RADO-001/02US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/JDA/	D1	ALDERMAN, A. "A Review of Cellulose Ethers in Hydrophilic Matrices for Oral Controlled-Release Dosage Forms," <i>Int. J. Pharm. Tech & Prod. Mfr.</i> (1984) 5(3) 1-9.			
	D2	ARMSTRONG <i>et al.</i> , "Role of Glutathione Depletion and Reactive Oxygen Species Generation in Apoptotic Signaling in a Human B Lymphoma cell line," <i>Cell Death Differ.</i> (2002) 9(3); 252-263.			
	D3	BAMBA <i>et al.</i> , "Release Mechanisms In Gelforming Sustained Release Preparation," <i>Int. J. Pharm.</i> (1979), 2, 307.			
	D4	BERGE <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharm. Sci.</i> (1977) 66:1-19.			
	D5	BROWN <i>et al.</i> Tirapazamine: Laboratory Data Relevant to Clinical Activity Anti-cancer Drug Design (1998), 13, 529-539.			
	D6	DURING <i>et al.</i> "Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization," <i>Ann. Neurol.</i> (1989) 25:351.			
	D7	HOWARD <i>et al.</i> , "Intracerebral Drug Delivery in Rats with Lesion-induced Memory Deficits," <i>J. Neurosurg.</i> (1989) 71:105.			
	D8	LANGER (1990) "New Methods of Drug Delivery," <i>Science</i> 249: 1527-1533			
	D9	LANGER "Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: a Review" <i>JMS-Rev. Macromol. Chem. Phys</i> (1983) C23(1), 61-126.			
	D10	LEVY <i>et al.</i> , "Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate," <i>Science</i> (1985) 228:190-196.			
	D11	NING <i>et al.</i> "The Antiangiogenic Agents SU5416 and SU 6668 Increase the Antitumor Effects of Fractionated Irradiation," <i>Radiat. Res.</i> (2002) 157(1): 45-51.			
	D12	ROSENTHAL <i>et al.</i> , "A Phase I Single-Dose Trial of Gadolinium Texaphyrin (Gd-Tex), a Tumor Selective Radiation Sensitizer Detectable by Magnetic Resonance Imaging," <i>Clin. Cancer Res.</i> , (1999), 739-745.			
↓					
/JDA/	D13	RUPNOW <i>et al.</i> , "p53 Mediates Apoptosis Induced by c-Myc Activation in Hypoxic or Gamma Irradiated Fibroblasts," <i>Cell Death Differ.</i> (1998) 5(2): 141-147.			

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/681,855
				Filing Date	10/07/2003
				First Named Inventor	Mark D. BEDNARSKI
				Group Art Unit	1614
				Examiner Name	Not yet assigned.
Sheet	3	Of	3	Attorney Docket Number	RADO-001/02US

/JDA/	D14	SAUDEK <i>et al.</i> , " <u>A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery</u> ," <i>N. Engl. J. Med.</i> (1989) 321:574-579.	
/JDA/	D15	SEFTON, " <u>Implantable Pumps</u> ," <i>CRC Crit. Ref. Biomed. Eng.</i> (1987) 14:201-240.	
/JDA/	D16	STRATFORD <i>et al.</i> <u>Bioreductive Drugs into the Next Millennium</u> <i>Anti-Cancer Drug Design</i> (1998), 13, 519-528.	
/JDA/	D17	TREAT <i>et al.</i> , " <u>Liposomes in the Therapy of Infectious Disease and Cancer</u> " Lopez-Berestein and Fidler (eds.), Liss, New York (1989), pp. 353-365.	
/JDA/	D18	VERMA <i>et al.</i> , " <u>Osmotically Controlled Oral Drug Delivery</u> " <i>Drug Dev. Ind. Pharm.</i> , (2000), 26:695-708.	
/JDA/	D19	VERSCOYLE <i>et al.</i> , " <u>Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation</u> ," <i>British J. Cancer</i> , 1999, 80, Suppl. 2, 96.	
/JDA/	D20	WILSON, <i>et al.</i> <u>Radiation-activated Prodrugs as Hypoxia-selective Cytotoxins: Model Studies with Nitroaryl methyl Quaternary Salts</u> <i>Anti-cancer Drug Design</i> (1998) 13, 663-685.	
/JDA/	D21	YAMAGUCHI <i>et al.</i> <u>Protodynamic Therapy with Motexafin Lutetium (Lu-Tex) Reduces Experimental Graft Coronary Artery Disease Transplantation</u> (2001) June 15:71(11) 1526-32.	

Examiner Signature	/James Anderson/	Date Considered	09/12/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
672396 v1/PA

¹ Unique citation designation number.

² Applicant is to place a check mark here if English language Translation attached.



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/681,855
				Filing Date	October 7, 2003
				First Named Inventor	Mark D. BEDNARSKI
				Group Art Unit	1614
Examiner Name	not yet assigned				
Sheet	1	of	1	Attorney Docket Number	RADO-001/02US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	(if known)		
/JDA/	P11	5,693,794		Nielsen	12-2-1997
/JDA/	P12	6,133,320		Yallimpalli et al.	10-17-2000

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T
		Office Code	Number	Kind			
				(if known)			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

Examiner Signature	/James Anderson/	Date Considered	09/12/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.